Mpi: First Patient Dosed In Phase 2 Study Of The Parp Inhibitor 2x121 For Breast Cancer | Latest News RSS feed

Mpi: First Patient Dosed In Phase 2 Study Of The Parp Inhibitor 2x121 For Breast Cancer - Latest News


MPI: First Patient dosed in Phase 2 Study of the PARP Inhibitor 2X-121 for Breast Cancer

"This Phase 2 study will enable us to rapidly evaluate the efficacy of our PARP inhibitor ... with Breast Cancer moving on to Multiple Myeloma and Prostate Cancer as the first steps. MPI`s DRP® tool h... read more

ONCY VENT : Decision on rights issue subject to approval at Extraordinary General Meeting

Become a member for free Sign up Sign up read more

Myriad Genetics: Exciting Alzheimer's Treatment In the Pipeline

All patients in the U.S. phase III study ... PARP (poly-ADPribose polymerase) inhibitor, to treat patients with breast cancer or ovarian cancer associated with an inherited mutation in one of the canc... read more

Looking for another news?


First Patient Dosed in Phase 2 Study of PARP/Tankyrase Inhibitor 2X-121 for Metastatic Breast Cancer

(“OV”) and Medical Prognosis Institute A/S (MPI:ST) today announced dosing of the first patient in a Phase 2, open-label clinical trial to investigate the anti-tumor effect and tolerability of 2X-121 ... read more


ONCY VENT : OV announces prolongation of option to buy back shares in OV SPV2 that holds dovitinib

Instead of treating all patients with a particular type of cancer, patients' tumors genes are screened first ... promising phase 2 product candidates and Danish OV-SPV 2 will test and potentially deve... read more

Myriad Genetics, Inc. F4Q08 (Qtr End 06/30/08) Earnings Call Transcript

Myriad Genetics, Inc. (NASDAQ:MYGN) F4Q08 (Qtr End 06/30/08) Earnings Call Transcript ... dose study in HIV positive, but treatment naïve patients and expect to initiate that study later this year. Ea... read more

MPI: First Patient dosed in Phase 2 Study of the PARP Inhibitor 2X-121 for Breast Cancer

Hoersholm, Denmark, June 26, 2018 - Medical Prognosis Institute A/S (MPI ... dosing of the first patient in a Phase 2, clinical study to investigate the anti-tumor effect and tolerability of 2X-121 in ... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us